Annaliesa S. Anderson

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19”.

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.12.293498

N/A

5.5DataRank · unranked

159 citations

Rhys Jones, Brandon J. Anson, Dan Arenson, Lisa Aschenbrenner, Malina A. Bakowski +44 more

A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL pro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

Journal of Virology(2021)10.1128/jvi.01819-20

N/A

5.2DataRank · unranked

142 citations

Adil Mohamed, Rachel A. Prescott, Ana M. Valero-Jimenez, Ludovic Desvignes, Rebecca E. O’Connor +12 more

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

The Journal of Infectious Diseases(2021)10.1093/infdis/jiab305

N/A

2.2DataRank · unranked

41 citations

James M. Anderson, Annaliesa S. Anderson, David Baker, Jay Bradner, Kyle R. Brimacombe +37 more

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Nature Communications(2021)10.1038/s41467-021-26239-2

N/A

0.855DataRank · unranked

297 citations

Rhys Jones, Brandon J. Anson, Dan Arenson, Lisa Aschenbrenner, Malina A. Bakowski +47 more

Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2)

BMJ Open(2022)10.1136/bmjopen-2022-062109

N/A

0.312DataRank · unranked

6 citations

Angela Hyder-Wright, Sherin Pojar, Tao Chen, Duolao Wang, Kelly Davies +16 more

385. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad500.455

N/A

0.104DataRank · unranked

1 citations

Lawrence Sher, Charu Sabharwal, Nicholas Kitchin, Sungeen Hill, Emily Wasserman +19 more

A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL pro inhibitor PF-00835231 as a potential new treatment for COVID-19

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.08.28.272880

N/A

0DataRank · unranked

24 citations

Adil Mohamed, Rachel A. Prescott, Ana M. Valero-Jimenez, Ludovic Desvignes, Rebecca E. O’Connor +12 more